Core Viewpoint - The company has submitted a registration application for its atropine eye drops (0.01% concentration, product code: NVK002) aimed at treating myopia progression in children, which has been accepted for review by the Australian Therapeutic Goods Administration [1] Group 1: Product Development - The application has passed preliminary review and will undergo further evaluation based on supportive results from the company's Phase III clinical trials [1] - NVK002 is a novel experimental topical eye solution designed to control myopia progression in children and adolescents [1] - The formulation of NVK002 addresses the instability of low-concentration atropine and is protected by intellectual property rights globally [1] Group 2: Market Position - NVK002 is currently one of the most advanced atropine candidates globally for treating myopia progression, targeting a broad patient group aged 3 to 17 years [1] - The product is preservative-free and is expected to have a shelf life of over 24 months [1]

Core Viewpoint - The company, Zhaoke Ophthalmology-B (06622.HK), has had its registration application for atropine sulfate eye drops (0.01% dosage, product code: NVK002) for treating myopia progression in children accepted by the Australian Therapeutic Goods Administration (TGA) [1] Group 1 - The TGA has officially notified the company that its application has passed the preliminary review and will undergo further evaluation [1] - The application is supported by results from the company's Phase III clinical trials [1] - NVK002 is a novel experimental topical eye solution designed to control myopia progression in children and adolescents [1] Group 2 - NVK002 features a patented formulation that successfully addresses the instability of low-concentration atropine, with intellectual property protection globally [1] - The eye drops are preservative-free and are expected to have a shelf life of over 24 months [1] - According to data from Zhi Shi Consulting, NVK002 is one of the most advanced atropine candidates globally for treating myopia progression, targeting a broad patient group aged 3 to 17 years [1]